Claritas Genomics Inc.

Claritas Genomics Inc. offers comprehensive genetic testing and diagnostic services, focusing on children with complex genetic disorders, providing vital insights for healthcare providers and families seeking clarity in challenging health situations. Claritas Genomics Inc. specializes in genetic testing and diagnostic services for pediatric patients with complex genetic conditions.

Founded in 2013 in Cambridge, US, the company has completed three funding rounds, with the latest being a Series B round raising USD 15 mn on January 26, 2015, featuring investors such as Boston Children's Hospital and Cerner Corporation. Tim Yu, the founder, has a notable history in the genomics sector, although details of previous ventures are not specified. Claritas Genomics specializes in genetic testing and diagnostic services tailored for children with complex genetic disorders. The company's offerings include advanced genetic sequencing and interpretative services aimed at providing timely and accurate results for families seeking answers to challenging health conditions.

By leveraging the clinical expertise of leading pediatric specialists, Claritas integrates innovative platform solutions to enhance patient care and drive new discoveries in genomics. The primary customers include healthcare providers, hospitals, and pediatric clinics, all of which utilize Claritas’s services to diagnose and manage various genetic disorders in children. Claritas Genomics operates in multiple geographical markets, extending its services across the United States and into select international regions, ensuring accessibility to high-quality genetic information globally. Claritas Genomics generates revenue through a structured service model that includes both direct-to-consumer offerings and partnerships with healthcare providers.

The company executes transactions primarily through service agreements with hospitals and clinics, where clients utilize Claritas's genetic testing for their patients. Pricing structures are aligned with the complexity and scope of the testing services provided, which may range from standard genetic panels to more comprehensive whole exome sequencing. Additionally, offerings like interpretative reports and ongoing support for healthcare professionals contribute to the overall service portfolio. The firm's flagship services are designed to meet the specific needs of pediatric patients, fostering a reliable flow of transactions that enhance its business sustainability.

Claritas Genomics plans to leverage the USD 15 mn raised in Series B funding to further develop its product offerings, particularly in advancing genetic testing technologies. The company aims to expand its services into new geographic markets, focusing on regions where pediatric genetic services are limited, with a goal to initiate these expansions by 2016. This funding will also support research and development initiatives intended to enhance the accuracy and efficiency of their testing processes.